Supernus Pharma (SUPN) Misses Q4 EPS by 25c

Supernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.43, $0.25 worse than the analyst estimate of $0.68. Revenue for the quarter came in at $167.33 million versus the consensus estimate of $180.38 million.

For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• Schwab's May activity shows margin loans nearly double
• Aspire Biopharma to acquire automotive supplier for $30 million